Sort   by:  
 Page size 
ProteomicsDetection of IGF2BP1 phosphorylation in vitro and in vivo via Pro-Alanase treatment
In this project we aim to identify phosphorylation sites of IGF2BP1 that have not been discovered yet in mass spec experiments due to insufficient coverage. To this end we used Pro-Alanase treatment that produced detectable peptides in regions that are not covered by commonly used approaches. IGF2BP...
ORGANISM(S): Homo sapiens (Human) Escherichia coli 
2024-11-13 | PXD056497 | Pride
Tyrosine phosphorylation Pro-alanase Igf2bp1 
ProteomicsIdentification of phosphorylation sites in human IGF2BP1 by immunoprecipitation coupled to mass spectrometry
Many RNA-binding proteins are regulated by posttranslational modifications, most commonly phosphorylation. IGF2BP1 is an RNA-binding protein, which regulates protein stability, translation and localization. Moreover, it was proposed to regulate mRNA stability and translation during proteotoxic stres...
ORGANISM(S): Homo sapiens (Human) 
2024-11-13 | PXD045761 | Pride
Q exactive hf-x Human Igf2bp1 Proteotoxic stress Hek293t Igf2bp3 
Transcriptomicsm6A modification profile in primary microglia with/without Igf2bp1 knockdown
Our study demonstrated that the expression of Igf2bp1 in activated microglia was significantly up-regulated, implying a role of Igf2bp1 in LPS-induced m6A modifications in microglia. To understand the roles of Igf2bp1 on LPS-induced m6A modification in microglia, we performed Igf2bp1 loss-of-functio...
ORGANISM(S): Mus musculus 
2022-12-31 | E-MTAB-11411 | biostudies-arrayexpress
Genomicsm6A modification profile in primary microglia with/without Igf2bp1 knockdown
m6A modification profile in primary microglia with/without Igf2bp1 knockdown
PRJEB50619 | ENA
GenomicsIGF2BP1 is a druggable, post-transcriptional super-enhancer of E2F-driven gene expression hallmark in cancer [IGF2BP1 KD in A549 (polyA RNA)]
IGF2BP1 is a druggable, post-transcriptional super-enhancer of E2F-driven gene expression hallmark in cancer [IGF2BP1 KD in A549 (polyA RNA)]
PRJNA610832 | ENA
GenomicsIGF2BP1 is a druggable, post-transcriptional super-enhancer of E2F-driven gene expression hallmark in cancer [IGF2BP1 KD in HepG2 (polyA RNA)]
IGF2BP1 is a druggable, post-transcriptional super-enhancer of E2F-driven gene expression hallmark in cancer [IGF2BP1 KD in HepG2 (polyA RNA)]
PRJNA612009 | ENA
GenomicsIGF2BP1 is a druggable, post-transcriptional super-enhancer of E2F-driven gene expression hallmark in cancer [IGF2BP1 KD in MV3 (total RNA)]
IGF2BP1 is a druggable, post-transcriptional super-enhancer of E2F-driven gene expression hallmark in cancer [IGF2BP1 KD in MV3 (total RNA)]
PRJNA612008 | ENA
GenomicsIGF2BP1 is a druggable, post-transcriptional super-enhancer of E2F-driven gene expression hallmark in cancer [IGF2BP1 KO in A-549 (polyA RNA)]
IGF2BP1 is a druggable, post-transcriptional super-enhancer of E2F-driven gene expression hallmark in cancer [IGF2BP1 KO in A-549 (polyA RNA)]
PRJNA610834 | ENA
GenomicsIGF2BP1 promotes SRF-dependent transcription in cancer in a m6A- and miRNA-dependent manner [IGF2BP1 and SRF KD in ES-2 (total RNA)]
IGF2BP1 promotes SRF-dependent transcription in cancer in a m6A- and miRNA-dependent manner [IGF2BP1 and SRF KD in ES-2 (total RNA)]
PRJNA476934 | ENA
GenomicsTumor suppressive function of IGF2BP1 in gastric cancer through decreasing MYC
Tumor suppressive function of IGF2BP1 in gastric cancer through decreasing MYC
PRJNA1019241 | ENA
Sort   by:  
 Page size